Attachment 1
|
Report
Update On |
16th February, 2001 |
|
|
|
|
Report on [Correct Name] |
ALEMBIC LIMITED |
|
|
|
|
Registered Office |
Alembic Road, Vadodara - 390 003, Gujarat, INDIA |
|
|
|
|
Tel. No. |
91-265-330550 / 380880 /
382804 |
|
Fax No. |
91-265-382134 / 382934 |
|
E-Mail |
|
|
Telex |
-- |
Attachment 2
SUMMARY
|
Incorporated |
1907 |
Status |
Satisfactory |
|
|
|
|
|
|
|
|
Registration No. |
33 |
Chief Executive |
Mr. Chirayu R. Amin |
|
|
|
|
|
|
|
|
Capital (Rs.) |
89.000 millions |
Payments |
Regular |
|
|
|
|
|
|
|
|
Sales (Rs.) |
3,954.400 millions |
Litigation |
-- |
|
|
|
|
|
|
|
|
Net Worth (Rs.) |
1,269.500 millions |
Banking Reputation |
Satisfactory |
|
|
|
|
|
|
|
|
No. of Employees |
3,000 |
Auditors |
K. S. Aiyar & Company |
|
|
|
|
|
|
|
|
Credit Rating |
A (See attachment 3) |
|
||
INDUSTRY
Chemical industry has been the fastest growing industry in India, since independence. Today, it has occupied a very important position in the national economy, ranking fourth after Iron & Steel, Engineering & Textiles. The basic inorganic and organic chemicals produced in the industry provide the basic building blocks for several downstream industries such as drugs, paper, synthetic rubber, dyestuff, plastics, polyesters, pesticides, paints, detergents, fertilisers, etc. The chemical process industry has a share of about 12% in the total manufacturing output of the country and close to 15% by value in the gross industrial production.
Chlor-Alkali industry, with a turnover of Rs.53 bn and accounting for over Rs.90 bn of investments, is perhaps the oldest segment of the chemicals process industry in the country. Over the last five decades, the industry has demonstrated an impressive track record of serving as a mother industry to development and growth of several downstream components. Caustic soda/ chlorine and soda ash are the two principal components of the industry, with caustic soda alone accounting for more than 75% of the sector.
Caustic soda is a general utility chemical and constitutes one of the important segments of the chemical process industry in India. The caustic soda industry in India, with a Rs.36 bn turnover, accounts for about 5% of the output of the chemical industry.
Chlorine is generated as a co-product along with caustic soda. It is a toxic and hazardous chemical is used in the manufacture of PVC, pulp & paper, bleaching powder and many other chemical compounds.
Soda ash is a versatile inorganic chemical with a vide variety of applications. It is largely used in the manufacture of detergents, glass, silicates and several downstream chemicals. It is known as Sodium Carbonate in chemical terms.
The industry is likely to continue to be a net importer although imports may be lower in the coming year due to larger capacities in the domestic market. The competitiveness of the industry will be severely tested as import duties on the furnished products come down further and foreign major seek to establish a toehold in the country.
************************
plant locations
Dist. Panchmahal, Gujarat
HISTORY
The company was incorporated on 30th July, 1907 at Vadodara in Gujarat under the name and style of Alembic Chemical Works Company Limited having Company Registration Number 33. Subsequently, the name of the company changed to present during August 1999.
The company was originally engaged in manufacturing chemicals, liquors, etc. However, from 1950's onwards, it ventured into pharmaceutical business, in the production of bulk drugs.
The company changed its name for truly reflecting the pharmaceutical nature of business being carried out and in the nominal value of equity shares from existing Rs. 100 per equity share to Rs. 10 per equity share.
Over the year, company has also developed other bulk drugs like Erythromycin, Roxithromycin and Azithromycin. The company is also in the formulations market and is producing number of items in therapeutic segments of which some of the products are the market leaders.
LEGAL FORM
It is a public limited liability company. The company's shares are listed on the Stock Exchanges.
DIRECTORS
|
Mr. Chirayu R. Amin |
Chairman & Managing Director |
|
Mrs. Malika C. Amin |
Whole-time Director |
|
Mr. Mohanlal V. Patel |
Director |
|
Mr. Babubhai R. Patel |
Director |
|
Mr. Hasmukhlal B. Parikh |
Director |
|
Mr. Ranjitbhai R. Patel |
Director |
|
Mr. Chunibhai B. Patel |
Director |
|
Mr. Ramanlal M. Kapadia |
Director |
|
|
|
|
Mr. R. M. Kapadia |
Company Secretary |
BUSINESS
The company is engaged in Manufacturing of Bulk Drugs such as Penicillin, Broad Spectrum Antibiotics, Hydroxocobalamin, Drugs & Chemicals, Protinules, Hard Gelatine Capsules and Ethyl Alcohol, Formulations such as Tablets & Capsules, Injectables and Oral Preparations & Ointments and various others such as Electric Power Generator, Polypropylene Fibre and Multifilament Yarn.
The Generic Names of Three Principal Products of the Company are :
|
Item Code No. (ITC Code) |
30042003 |
|
Product Description |
Erythromycin
Formulations |
|
|
|
|
Item Code No. (ITC Code) |
30041000 |
|
Product Description |
Penicillin
& Combination Formulations |
|
|
|
|
Item Code No. (ITC Code) |
30042003 |
|
Product Description |
Roxithromycin
Formulations |
The company's installed capacity and licensed capacity are as under :
|
Class of Goods |
Unit
|
Licensed Capacity |
Installed Capacity |
|
|
|
|
|
|
Bulk Drugs : |
|
|
|
|
Penicillin |
MMU |
1,000 |
600 |
|
Broad Spectrum Antibiotics |
M.T. |
148,200 |
148,100 |
|
Hydroxocobalamin |
Kgs. |
20 |
12 |
|
Drugs & Chemicals |
M.T. |
2,329 |
1,696 |
|
Potrinules |
M.T. |
500 |
500 |
|
Hard Gelatine Capsules |
Million Nos. |
600 |
400 |
|
Ethyl Alcohol |
K. Lit. |
3,300 |
3,300 |
|
|
|
|
|
|
Formulations : |
|
|
|
|
Tablets & Capsules |
Million Nos. |
5,396.411 |
2,158.000 |
|
Injectables |
Million Nos. |
320.222 |
224.543 |
|
Oral Preparations & Ointments |
M.T. |
20,484.980 |
5,934.616 |
|
|
|
|
|
|
Others : |
|
|
|
|
Electric Power Generation |
M.W. |
20 |
8 |
|
|
|
|
|
|
Neomer Division
: |
|
|
|
|
Polypropylene Fibre |
M.T. |
6,000 |
4,300 |
The company's product comprises of anti-infectives, NSAIDs and cough/cold preparations. It also manufactures the major intermediate drug Penicillin-G in-house and sells the surplus.
The product range includes Penicillin to quninolone ciprofloxacin based formulations, macrolides. The company also offers ayurvedic medicine Glycodin.
Top 5 brands contribute over 55% of company's sales. Althrocin is the #22 brand and has a 29.3% market share among macrolide anti-infectives. Roxid ranks #3 with 13.7% market share. Its' other macrolide brand is Azithral. The company has also quinolone antibiotic brands Norbid and Ciprowin. Zeet having 2.8% market share among allopathic cough syrup. Wikoryl is the 2nd most popular cold medication.
The company launched five new formulations including clarithromycin under the brand name Claritho. In F12/97 the company introduced some line extensions namely Roxid liquid and Nimegegesic gel. In F12/96, the company introduced new products including Nimesulide-M an NSAID and a new cough syrup.
The company's veterinary division ranks 6th in Indian domestic market.
In bulk drugs, almost half the sales are of Penicillin-G. The company has installed capacity for Pen-G as 600 mmupa and Erythromycin as 100 tons p.a. the company plans to manufacture Cephalosporin-C
In F12/98, exports grew by 36%yoy. The company is exporting its product to Asia Pacific and Africa, HongKong, Vietnam, Russia, Ukraine and Nairobi.
In FY12/98, the profitability of the company increased significantly due to higher sales value and change in the product mix. The return ratios improved significantly in the last couple of years as the company improved its overall operational efficiency.
During the year 1998-99 the sales turnover of the company was Rs. 3954.400 millions as against Rs. 3872.500 millions in the year 1997-98. The net profit was Rs. 284.900 millions as against Rs. 165.800 millions in the year 1997-98.
The company has received ISO-9002 certification from an accreditation agency for manufacture and marketing of bulk drugs and formulations for domestic sales and exports.
The company entered into technical collaboration for manufacture of cephalosporin-C and 7-ACA. Cephalosporins business is rapidly growing due to expiry of patent of few cephalosporin drugs and substantial export sales potential.
Along with this project the company will go for third gas turbine based co-generation power plant not only to meet power requirement of the project but also to reduce substantially the overall energy cost of the company.
The company employs around 3000 persons in its' set up.
The company's fixed assets of important value includes Freehold Land, Pharma & Other Building, Employees Quarters, Pharma & Other Plant & Machinery, Railway Siding, Furniture & Fixtures, Office Equipments and Vehicles.
associates
K Alembic Glass
K Paushak Limited
K Shreno Limited
K Light Publications Limited
K Aavaran Limited
K Nirayu Private Limited
K Darshak Limited
K Whitefield Investment & Leasing Company Private Limited
K Shreno Investment & Finance Limited
K Sierra Investments Limited
K Whitefield Chemtech Private Limited
K PSU Chemicals Private Limited
subsidiaries
K Algen Limited
BANKERS
K ABN-AMRO Bank N V
K Bank of Baroda
K Indian Bank
K ICICI Banking Corporation Limited
K ING Bank NV
K UTI Bank of India
K Vijaya Bank
AUDITORS
K K. S. Aiyar & Company
Chartered
Accountants
FINANCIAL INFORMATION
The company's latest financial information for the period ended 31st December, 1999 is enclosed herewith.
The company’s Summarised Results for the period ended 31st December, 2000 were as under :
[figures are in Rupees Millions]
|
PARTICULARS |
|
|
31.12.2000 |
|
|
|
|
|
|
Sales
Turnover |
|
|
4,260.0 |
|
Other
Income |
|
|
37.3 |
|
Total Income |
|
|
4,297.3 |
|
|
|
|
|
|
Total
Expenditure |
|
|
3,602.3 |
|
|
|
|
|
|
Operating
Profit |
|
|
695.0 |
|
Interest |
|
|
241.5 |
|
Gross
Profit |
|
|
453.5 |
|
Depreciation |
|
|
123.1 |
|
Tax
|
|
|
61.1 |
|
Reported
PAT |
|
|
269.3 |
CAPITAL STRUCTURE
|
Authorised Capital : |
|||
|
1,000,000 |
Equity Shares of Rs.100/- each |
Rs.100.000 millions |
|
|
1,000,000 |
Redeemable Cumulative Preference Shares of Rs.100/- each |
Rs.100.000 millions |
|
|
3,000,000 |
Redeemable Preference Shares of Rs.100/- each |
Rs.300.000 millions |
|
|
GRAND TOTAL |
Rs.500.000 millions |
||
|
|
|||
|
Issued, Subscribed &
Paid-up Capital : |
|||
|
8,900,000 |
Equity shares of Rs. 10 each |
Rs.89.000 millions |
|
COMMENTS
Subject is a well-established and reputed pharmaceutical company. Available information indicated high financial responsibility of the company. Directors are reported as experienced, respectable and resourceful businessmen. Their trade relations are fair. General financial position is good. Business is active. Payments are usually correct and as per commitments.
The company can be considered normal for business dealings at usual trade terms and conditions.
The company can be regarded as a promising business partner in a long-run.
PRICE MOVEMENT
|
HIGHS
& LOWS OF EQUITY SHARES + |
|||||||
|
|
High Rs. |
Low Rs. |
|
1998-1999 |
1999-2000 |
||
|
High Rs. |
Low Rs. |
High Rs. |
Low Rs. |
||||
|
-- |
-- |
-- |
Jul. |
1,243.00 |
985.00 |
2,675.00 |
2,000.00 |
|
1989 |
450.00 |
260.00 |
Aug. |
1,119.25 |
962.00 |
284.10 |
284.10 |
|
1990 |
460.00 |
255.00 |
Sep. |
990.00 |
900.00 |
394.50 |
306.80 |
|
1991 |
965.00 |
220.00 |
Oct. |
964.50 |
890.00 |
665.45 |
342.00 |
|
1992 |
2,000.00 |
725.00 |
Nov. |
990.00 |
875.00 |
529.00 |
425.80 |
|
1993 |
1,450.00 |
485.00 |
Dec. |
1,189.50 |
900.00 |
673.80 |
450.35 |
|
1994 |
3,800.00 |
1,500.00 |
Jan. |
1,420.50 |
1,081.00 |
695.45 |
495.00 |
|
1995 |
3,150.00 |
1,320.00 |
Feb. |
1,939.00 |
1,534.00 |
515.00 |
380.50 |
|
1996 |
1,600.00 |
770.00 |
Mar. |
2,385.00 |
1,994.25 |
395.00 |
272.00 |
|
1997 |
1,250.00 |
475.00 |
Apr. |
2,351.25 |
1,964.00 |
308.45 |
235.00 |
|
1998 |
1,389.00 |
441.00 |
May |
2,277.90 |
1,885.00 |
242.95 |
185.00 |
|
1999 |
2,675.00 |
284.10 |
Jun. |
2,190.00 |
1,926.00 |
211.85 |
174.65 |
|
+
Mumbai |
|||||||
CAPITAL HISTORY
|
Year |
Details |
|
1998-99 |
1,500,000
Non-Convertible Cumulative Preference Shares were redeemed during the year. |
|
|
|
|
1996-97 |
1,000,000
Preference Shares alloted on preferential basis. |
|
|
|
|
1995-96 |
164,732
Equity Shares of Rs.100/- each at a premium of Rs.850/- per share issued to
the shareholders on rights basis. |
|
|
|
|
1985-86 |
66,900
Equity Shares allotted without payment in cash to the shareholders of Neomer Limited
on its merger. 2,000 Preference Shares redeemed. |
|
|
|
|
1984-85 |
2,000
Preference Shares redeemed. |
|
|
|
|
1980-83 |
Redeemed
1,000 Preference Shares each on 01.01.1978, 01.01.1979, 01.11.1980,
01.01.1981, 01.01.1982 and 01.01.1983. |
|
|
|
|
1977 |
6Ľ%
Preference and 6% III Preference Shared converted to 9% Redeemed Preference
Shares from 01.01.1976. 5,000 – 5% Preference Shares redeemed at Rs.105/- per
share on 01.01.1977. |
|
|
|
|
1968 |
In March
1971, 57,487 Right Equity Shares issued at par in the proportion of 1:5. |
|
|
|
|
1968 |
25.080
Right Equity Shares at par in proportion of 5:41. |
|
|
|
|
1959-61 |
In
1959, 20,000 Right Equity Shares offered at par in the proportion of 1:4 to all
classes. In 1961, 10,000 Right Equity Shares offered at par in proportion of
1:1 to classes. |
ABRIDGED BALANCE SHEET AS ON 31ST DECEMBER, 1999
[figures are in Rupees Millions]
|
SOURCES OF FUNDS |
31.12.1999 |
31.12.1998 |
31.12.1997 |
|
SHAREHOLDERS FUNDS |
|
|
|
|
1] Share Capital |
89.0 |
239.0 |
157.6 |
|
2] Reserves & Surplus |
1,180.5 |
936.6 |
591.4 |
|
|
|
|
|
|
LOAN FUNDS |
|
|
|
|
1] Secured Loans |
948.6 |
808.9 |
798.1 |
|
2] Unsecured Loans |
407.0 |
376.4 |
369.7 |
|
|
|
|
|
GRAND TOTAL
|
2,625.1 |
2,360.9 |
1,916.8 |
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1,332.9 |
1,359.3 |
1,223.2 |
|
Capital work-in-progress |
147.7 |
37.7 |
58.1 |
|
|
|
|
|
|
INVESTMENTS |
70.9 |
73.4 |
56.4 |
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
Inventories |
523.3 |
519.7 |
472.5 |
|
Sundry Debtors |
469.4 |
380.2 |
347.9 |
|
Cash & Bank Balances |
35.7 |
25.9 |
28.7 |
|
Loans & Advances |
522.1 |
389.4 |
215.5 |
|
Total Current Assets |
1,550.5 |
1,315.2 |
1,064.6 |
|
Less : |
|
|
|
|
Current Liabilities |
380.7 |
325.3 |
419.3 |
Provisions |
133.7 |
121.9 |
79.4 |
|
Net Current Assets |
1.036.1 |
868.0 |
565.9 |
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
37.5 |
22.5 |
13.2 |
|
|
|
|
|
GRAND TOTAL
|
2,625.1 |
2,360.9 |
1,916.8 |
IMPORTANT FINANCIAL INFORMATION FOR LAST Three PERIODS
[figures are in Rupees Millions]
|
PARTICULARS |
31.12.1999 |
31.12.1998 |
31.12.1997 |
|
Sales Turnover |
3954.4 |
3872.5 |
3214.3 |
|
[including other income] |
|
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
324.9 |
187.3 |
82.9 |
|
Provision for Taxation |
40.0 |
21.5 |
8.8 |
|
Profit/(Loss) After Tax |
284.9 |
165.8 |
74.1 |
|
|
|
|
|
|
Dividend |
25.2 |
20.3 |
13.9 |
|
|
|
|
|
|
Earnings in Foreign Currency : |
|
|
|
|
Export Earnings |
NA |
NA |
NA |
|
Other Earnings |
NA |
NA |
NA |
|
Total Earnings |
NA |
NA |
NA |
|
|
|
|
|
|
Imports : |
|
|
|
|
Raw Materials |
NA |
NA |
NA |
|
Components & Spares |
NA |
NA |
NA |
|
Capital Goods |
NA |
NA |
NA |
Total Imports
|
NA |
NA |
NA |
|
|
|
|
|
Expenditures :
|
|
|
|
|
Raw
Materials |
1,202.4 |
1,218.9 |
1,022.1 |
|
Excise
Duty |
404.2 |
375.2 |
317.2 |
Power & Fuel Cost
|
291.4 |
231.8 |
185.4 |
Other Manufacturing Expenses
|
433.2 |
504.2 |
431.4 |
Employee Cost
|
334.9 |
346.7 |
310.7 |
Selling and Administration
Expenses
|
569.9 |
528.8 |
504.4 |
Miscellaneous Expenses
|
21.1 |
73.1 |
32.9 |
Interest & Financial
charges
|
265.8 |
278.3 |
257.7 |
Depreciation
|
106.6 |
128.2 |
69.6 |
Total Expenditures
|
3,629.5 |
3,685.2 |
3,131.4 |
Attachment 3
|
SCORE SHEET |
|
SCORE |
CREDIT RATING |
STATUS |
PROPOSED CREDIT LINE |
|
>86 |
Aaa |
Possesses an
extremely sound financial base with the strongest capability for timely
payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate
working capital. No caution needed for credit transaction. It has above average
(strong) capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial &
operational base are regarded healthy. General unfavourable factors will not
cause fatal effect. Satisfactory capability for payment of interest and principal
sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is
considered normal. Capable to meet normal commitments. Maybe drawn to
slightly difficult position as unfavourable conditions arise. Minimal assurance
for timely payment on interest and principal sums |
Moderate |
|
26-40 |
B |
Unfavourable &
favourable factors carry similar weight in credit consideration. Capability
to overcome financial difficulties seems comparatively limited or considered
not known. Capability to pay both interest and principal sums is doubtful |
Small |
|
11-25 |
Ca |
Adverse factors are
apparent. Repayment of interest and principal sums in default or expected to
be in default upon maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk
exists. Caution needed to be exercised |
Credit not recommended |
Attachment 4
INDIA
INDIA, one of the oldest civilisations with a kaleidoscopic variety and rich cultural heritage. It ahs achieved multifaceted socio-economic progress during the last 53 years of its independence. India has become self-sufficient in agricultural production and is now the tenth industrialised country in the world and the sixth nation to have gone into outer space to conquer nature for the benefit of the people. It covers an area of 3,287,2631 sq.km., extending from the snow-covered Himalayan heights to the tropical rain forests of the south. As the seventh largest country in the world, India stands apart from the rest of Asia, marked off as it is by mountains and the sea, which give the country a distinct geographical entity. Bounded by the Great Himalayas in the north, it stretches southwards and at the Tropic of Cancer, tapers off into the Indian Ocean between the Bay of Bengal on the east and the Arabian Sea on the west.
Lying entirely in the northern hemisphere, the mainland extends between latitudes 8°4’ and 37°6’ north, longitudes 68°7’ and 97°25’ east and measures about 3,214 km from north to south between the extreme latitudes and about 2,933 km from east to west between the extreme longitudes. It has a land frontier of about 15,200 km. The total length of the coastline of the mainland, Lakshadweep Islands and Andaman & Nicobar Islands is 7,516.6 km.
The countries having a common border with India are Afghanistan and Pakistan to the north-west, China, Bhutan and Nepal to the north, Myanmar to the east and Bangladesh to the east of West Bengal. Sri Lanka is separated from India by a narrow channel of sea formed by the Palk Strait and the Gulf of Mannar.
Rivers in India may be classified as : (i) Himalayan rivers; (ii) Peninsular rivers; (iii) Coastal rivers and (iv) rivers of Inland drainage basins.
The climate in India may be broadly described as tropical monsoon type. There are four seasons: (i) Winter (January-February); (ii) Hot-weather Summer (March-May); (iii) Rainy South-Western Monsoon (June-September) and (iv) Post-Monsoon, also known as North-East Monsoon in the Southern Peninsula (October-December). India’s climate is affected by two seasonal winds – the north-east monsoon and the south-west monsoon. The north-east monsoon commonly known as winter monsoon blows from land to sea whereas south-west monsoon known as summer monsoon blows from sea to land after crossing the Indian Ocean, the Arabian Sea and the Bay of Bengal. The south-west monsoon brings most of the rainfall during the year in the country. It is now possible to make forecast about the monsoon rains successfully with developed models and trained manpower.
India’s populations, as on 1st March, 1991 stood at 846.30 millions (439.23 million males and 407.07 million females). This includes the projected population of 7.72 million of Jammu & Kashmir. The second most populous country, India is the home of 16 percent of world’s population. The country, however, accounts for 2.42 percent of the total world area.
The population in India as recorded at each decenial census from 1901 has grown steadily except for a decrease during 1911-21. Decadel growth of population from 1901 is shown in the table below :
POPULATION
Year
|
Population |
Decade
Growth Rate (percent)1 |
Average
Annual Exponential Growth Rate (percent) |
Progressive
Growth Rate over 1901 |
|
1901 |
238,396,327 |
-- |
-- |
-- |
|
1911 |
252,093,390 |
+5.75 |
0.56 |
+5.75 |
|
1921 |
251,321,213 |
-0.31 |
-0.03 |
+5.42 |
|
1931 |
278,977,327 |
+11.00 |
1.04 |
+17.02 |
|
1941 |
318,660,580 |
+14.22 |
1.33 |
+33.67 |
|
1951 |
361,088,090 |
+13.31 |
1.25 |
+51.47 |
|
1964 |
439,934,771 |
+21.51 |
1.96 |
+84.25 |
|
1971 |
548,159,652 |
+24.80 |
2.20 |
+129.94 |
|
1981 |
683,329,097 |
+24.66 |
2.22 |
+186.64 |
|
1991 |
846,302,688 |
+23.85 |
2.14 |
+255.00 |
INDIAN INDUSTRY
India started has quest for industrial development after independence in 1947. The Industrial Policy Resolution of 1948 marked the beginning of the evolution of the Indian Industrial Policy.
As per Quick Estimate of the Index of Industrial Production, the overall growth of Industrial Production during 1999-2000 was 8 percent. Intermediate Goods recorded a growth of 15 percent. Consumer durable goods recorded a growth of 12.2 percent over 1998-99. Consumer non-durables recorded a growth of 4 percent during 1999-2000 over the corresponding period last year.
While the overall industrial growth was 8 percent, the core infrastructure sectors achieved an average growth rate of 8.5 percent during the financial year 1999-2000.
The performance of six infrastructure industries is given herebelow :
|
Sr. No. |
Industry |
Weight |
1995-96 |
1996-97 |
1997-98 |
1998-99 |
1999-2000 |
|
1. |
Electricity |
10.1690 |
8.3 |
3.8 |
6.6 |
6.6 |
7.1 |
|
2. |
Coal |
3.2216 |
6.4 |
5.7 |
3.6 |
-2.0 |
3.3 |
|
3. |
Steel |
5.1278 |
21.9 |
5.8 |
6.3 |
1.3 |
12.5 |
|
4. |
Crude Petroleum |
4.1721 |
7.1 |
-4.7 |
2.9 |
-3.4 |
-2.2 |
|
5. |
Petroleum Refinery Products |
2.0021 |
3.9 |
7.0 |
3.7 |
5.2 |
25.3 |
|
6. |
Cement |
1.9891 |
11.5 |
9.6 |
9.1 |
5.7 |
14.0 |
|
Overall |
26.6817 |
10.5 |
3.0 |
5.6 |
2.9 |
8.5 |
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit |
Indian
Rupees |
|
US Dollar |
1 |
Rs.43.35 |
|
UK Pound |
1 |
Rs.68.08 |
|
Euro |
1 |
Rs.40.52 |
Attachment 5
ACKNOWLEDGEMENT
Dear Sir/Madam,
As part of our control
system, please fax/email us this note
upon receipt of this report. If we do not receive the acknowledgement within 24
hours, we will assume that our report meets your requirement. If you have any
suggestion to help us improve our reports and services, please do not hesitate to
let us know.
Thank you.
______________________________________________________________________________
To : MIRA INFORM PRIVATE
LIMITED
From :
To :
Feedback – Please tick
the appropriate box.
------------------------------------------------------------
|
|
GOOD |
FAIR |
POOR |
|
|
|
|
|
|
Content |
[
] |
[
] |
[
] |
|
Layout and
Presentation |
[
] |
[
] |
[
] |
|
Speed of Delivery |
[
] |
[
] |
[
] |
|
Overall Impression |
[
] |
[
] |
[
] |
Further Comments/Suggestion :
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
_____________________________
Company’s Stamp &
Signature